Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Biocartis and VIB Join Forces

Published: Monday, December 09, 2013
Last Updated: Sunday, December 08, 2013
Bookmark and Share
Company will develop a new CRC assay for MSI biomarker detection.

Biocartis and VIB have announced their exclusive license agreement on a novel panel of microsatellite instability (MSI) biomarkers for several cancers, in particular colorectal cancer (CRC).

This agreement will enable Biocartis to develop a unique and user-friendly assay, whereby MSI biomarkers can simply and rapidly be detected by Biocartis’ molecular diagnostics platform Idylla™.

Biocartis’ innovative platform and oncology assays
Biocartis develops the innovative user-friendly diagnostic platform Idylla™, for the molecular analysis of clinical samples.

Biocartis also develops a wide range of clinically relevant tests for various diagnostic areas primarily in the field of oncology. For the development of a new assay for microsatellite instability, Biocartis joins forces with the world-renowned research institute VIB.

Novel MSI biomarkers for colorectal, ovarian and other cancers
Microsatellite instability (MSI) is one of the premier molecular markers in CRC but is also important in ovarian, endometrial and gastric cancers. MSI evolves as a result of inactivation of the DNA mismatch repair (MMR) system and can be found in approximately 15% of all CRCs.

A completely novel set of MSI-markers is now introduced by Prof. Dr. Diether Lambrechts (Vesalius Research Center, VIB, KU Leuven) through whole genome sequencing of colon and endometrial cancers with MMR deficiency.

Prof. Lambrechts commented: “We were able to prove that our novel set of markers has a higher specificity and sensitivity than the current golden standard for MSI. I am very excited about this collaboration with Biocartis, as the clinical application of these markers will facilitate the improved detection of tumors with MSI.”

New colorectal cancer assay for simple and rapid detection
As a result of the license agreement with VIB, Biocartis will develop a new CRC assay for MSI biomarker detection. Today, MSI-testing is vastly underused due to the technical complexity of the current laboratory-developed assays. The availability of a simple and user-friendly assay on Biocartis’ Idylla™ platform has the potential to unlock greatly this considerable market.

Geert Maertens, CSO at Biocartis, commented: “This agreement is a nice example of valorization of new biomarkers from centers of excellence such as the VIB-lab of Prof. Lambrechts. Together with our core panel of colon cancer mutations and the recently in-licensed EGFR S492R mutation from Hospital del Mar, we are building a superior and unique menu for colon cancers assays on our Idylla™ platform.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Invetech and Biocartis Announce Biomarker Collaboration
Agreement supporting global development and manufacture of instrument to analyze protein and nucleic acid biomarkers continues multi-year relationship.
Wednesday, April 16, 2014
Biocartis and Hospital del Mar Join Forces
License agreement to develop diagnostic colon cancer test.
Monday, October 21, 2013
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!